# OnCo record nct07517198 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07517198/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07517198", "NCT07517198" ;
  schema:name "Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors"@en ;
  schema:description "A phase 1 trial of REC-4539 run by Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07517198/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07517198> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/rcc/>, <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/hcc/>, <https://onco.cc/cancers/gastric/>, <https://onco.cc/cancers/tnbc/> ;
  onco:drugs <https://onco.cc/drugs/rec-4539/> ;
  onco:companies <https://onco.cc/companies/recursion/> .